• SHAPERON First-in class anti-inflammatory NME targeting TGR5

    For atopic dermatitis, ulcerative colitis, sepsis and Alzheimer’s disease

  • SHAPERON API Increases number of immune regulatory cells resolving inflammation

    such as myeloid-derivedspan suppressor cells or regulatory T cells

  • SHAPERON Novel platform for nanobody-drug conjugates

    for enhanced tissue distribution and lower side effects of conventional ADC

1 3